Page 13 - கோர் ஒன்று ஆய்வகங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Core One Labs Inc.: Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FSE:LD62)(WKN:A2P8K3) (the Company ) is pleased to announce that in collaboration with Ketamine Infusions Centers of Texas LLC (KICT) it is exploring a development program for N-dimethyltryptamine (DMT) assisted psychotherapy to address anxiety and depression. In December 2020, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (UK) approved the world s first clinical trial testing the efficacy and safety of DMT as a treatment for depression. The first phase of the study (Phase I) commenced in January 2021, with proof of concept Phase IIa expected to follow shortly thereafter. The trial is being conducted by Small Pharma Ltd., a neuropharmaceutical company, working in collaboration with the Centre for Psychedelic Research at Imperial College London

United statesUnited kingdomCosta ricaBritish columbiaCity ofBufo alvariusJoel shackerSmall pharma ltdCore one labs incCanadian securities exchangeHealth canadaKetamine infusions centers of texasHealthcare products regulatory agencyCore one labsKetamine infusions centersPsychedelic research